Pulmonary artery denervation – the time has come for a multicentre blinded randomised controlled trial

Lang, Irene

doi:10.4244/eijv15i8a122

Search citation statements

Order By: Relevance

Paper Sections

Select...

Pulmonary Artery Denervation1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite this, percutaneous PA denervation is already being applied to patients with PH secondary to left heart disease [80,[83][84][85]97,101]. Given the uncertainty that still many experts share about the effectiveness of PA denervation as a treatment for chronic PH [11,102,103], there is a need for randomized, controlled, multicenter blinded studies in this field [104,105]. Blinding is particularly important because the placebo effect has proven to be very relevant in previous renal denervation trials [106].…”

Section: Pulmonary Artery Denervationmentioning

confidence: 99%

Neurohormonal Modulation as a Therapeutic Target in Pulmonary Hypertension

García‐Lunar

Pereda

Ibáñez

et al. 2020

Cells

View full text Add to dashboard Cite

The autonomic nervous system (ANS) and renin-angiotensin-aldosterone system (RAAS) are involved in many cardiovascular disorders, including pulmonary hypertension (PH). The current review focuses on the role of the ANS and RAAS activation in PH and updated evidence of potential therapies targeting both systems in this condition, particularly in Groups 1 and 2. State of the art knowledge in preclinical and clinical use of pharmacologic drugs (beta-blockers, beta-three adrenoceptor agonists, or renin-angiotensin-aldosterone signaling drugs) and invasive procedures, such as pulmonary artery denervation, is provided.

show abstract